Witness Testimony

Navid Sadikali, a medical imaging executive with more than two decades of experience designing large-scale healthcare technologies, presented a six-part framework combining business and scientific narratives. He described pre-pandemic activities including Event 201, material transfer agreements involving Moderna and NIAID, and early lockdown marketing contracts, arguing these demonstrated business leadership preceding formal pandemic declarations. He characterized these developments as evidence that economic and institutional actors shaped early pandemic response decisions.
He then critiqued PCR testing methodology, explaining amplification cycles using a photocopier analogy and asserting that high cycle thresholds could generate false positives by detecting viral fragments rather than active infection. He argued that widespread PCR testing overstated case counts and influenced hospital protocols and public perception. He maintained that case, hospitalization, and mortality statistics were uncertain due to test design and laboratory variability.
Sadikali further contended that vaccine efficacy calculations were distorted by classification practices that categorized infections occurring within 14 days of injection as “unvaccinated.” Citing Pfizer trial withdrawal numbers and provincial reporting definitions, he alleged this binning approach artificially inflated reported efficacy. He also argued that injected vaccines generate systemic IgG antibodies rather than mucosal IgA immunity, making sterilizing immunity biologically implausible. He concluded by emphasizing natural immune mechanisms, including T cells and natural killer cells, as under-recognized protective systems and encouraged re-evaluation of pandemic data and public health assumptions.